v**********m
发帖数: 5516 | 1 ARNA 1.48 +0.09 (6.47%)
VVUS 8.88 +0.41 (4.84%)
OREX 1.58 +0.21 (14.91%) | y***q
发帖数: 4147 | 2 百分之20以下不叫彪好不好？
没过过好时候？
【在 v**********m 的大作中提到】
: ARNA 1.48 +0.09 (6.47%)
: VVUS 8.88 +0.41 (4.84%)
: OREX 1.58 +0.21 (14.91%)
| v**********m
发帖数: 5516 | 3 穷怕了啊，大S。
【在 y***q 的大作中提到】
: 百分之20以下不叫彪好不好？
: 没过过好时候？
| y*****l
发帖数: 5997 | 4 恭喜！
【在 v**********m 的大作中提到】
: 穷怕了啊，大S。
| K*******n
发帖数: 1466 | 5 明天有一个垃圾中的垃圾可能会彪不止40哥破损。
【在 y***q 的大作中提到】
: 百分之20以下不叫彪好不好？
: 没过过好时候？
| y*****l
发帖数: 5997 | 6 生物还是金融？
【在 K*******n 的大作中提到】
: 明天有一个垃圾中的垃圾可能会彪不止40哥破损。
| K*******n
发帖数: 1466 | 7 是transportation services。不是HRZ. | y***q
发帖数: 4147 | 8 你的cdti还在吗？
我还在
【在 K*******n 的大作中提到】
: 明天有一个垃圾中的垃圾可能会彪不止40哥破损。
| K*******n
发帖数: 1466 | | B******o
发帖数: 565 | 10 SINO, CIIC, SIHI 还是 CALI？ 呵呵
【在 K*******n 的大作中提到】
: 是transportation services。不是HRZ.
| | | K*******n
发帖数: 1466 | | S****S
发帖数: 923 | | S****S
发帖数: 923 | | K*******n
发帖数: 1466 | | S****S
发帖数: 923 | 15 出什么事了？
【在 K*******n 的大作中提到】
: kao !
| f**********g
发帖数: 2252 | 16 The Company held a special meeting of stockholders on September 16, 2011.
The Company's outstanding common stock, Series A Voting Preferred Stock and
Series B Convertible Preferred Stock voted together as a single class on all
proposals, with each share of common stock and Series A Voting Preferred
Stock entitled to one vote and each share of Series B Convertible Preferred
Stock entitled to 42.6652 votes. At the meeting, the following matters were
voted on, and the following votes were cast, by the stockholders:
The Agreement and Plan of Merger, also referred to herein as the "Merger
Agreement," between the Company and its recently formed, wholly-owned
subsidiary, YRC Merger Sub, Inc., a Delaware corporation, was approved. The
merger will be effective upon the filing of the Certificate of Merger with
the Delaware Secretary of State.
For Against Abstain Broker Non-Votes 210,631,026 1,161,383 193,559 0
The adjournment of the Special Meeting, if necessary, to solicit additional
proxies, if there were not sufficient votes at the time of the special
meeting to approve the Merger Agreement, was approved.
For Against Abstain Broker Non-Votes 210,453,603 1,308,569 223,796 0
Adjournment of the special meeting was not necessary because there were
sufficient votes at the time of the special meeting to adopt the Merger
Agreement. | v**********m
发帖数: 5516 | 17 我买了个loser。
【在 y*****l 的大作中提到】
: 恭喜！
| K*******n
发帖数: 1466 | 18 “哥破损”
靠，一语成。。。，原来是被自己诅咒了。
“帅哥”进去，“公公”出来，真的破损了。
彻彻底底废了！
求包子，求安慰，求包养！
【在 K*******n 的大作中提到】
: 明天有一个垃圾中的垃圾可能会彪不止40哥破损。
| a****c
发帖数: 339 | 19 你干嘛要加这三个没有意义的字。。。？
包子一个安慰下。
版上美女包你吧。
您转给 KDnewborn,现金(伪币):10,收取手续费:0.1
【在 K*******n 的大作中提到】
: “哥破损”
: 靠，一语成。。。，原来是被自己诅咒了。
: “帅哥”进去，“公公”出来，真的破损了。
: 彻彻底底废了！
: 求包子，求安慰，求包养！
| a****c
发帖数: 339 | 20 我也是CDTI.
最近在想可不可以做CDTI的波段，3.6-3.9之间已经晃悠了很久了。
【在 K*******n 的大作中提到】
: 在呀。下星期总体天气好的话，应该要起来了吧。
| K*******n
发帖数: 1466 | 21 谢谢啊！
【在 a****c 的大作中提到】
: 你干嘛要加这三个没有意义的字。。。？
: 包子一个安慰下。
: 版上美女包你吧。
: 您转给 KDnewborn,现金(伪币):10,收取手续费:0.1
| v**********m
发帖数: 5516 | 22 Orexigen Revives Obesity Drug Development With FDA Agreement
Q
By Ryan Flinn - Sep 20, 2011 4:38 PM ET
inShare1
More
Print
Email
Orexigen Therapeutics Inc. (OREX) is renewing development of the
experimental obesity drug Contrave after reaching an agreement with U.S.
regulators to further study heart risks.
Orexigen, one of three companies with rival obesity treatments competing for
approval, will start a two-year clinical trial of about 10,000 patients in
the first half of next year, aiming to receive clearance for Contrave from
the Food and Drug Administration in 2014, the La Jolla, California- based
company said today in a statement.
“It’s very positive news,” Michael Narachi, Orexigen president and chief
executive officer, said in an interview. “This drug, which we always
believed could benefit patients, has a clear path to market.”
Orexigen announced June 3 it would halt U.S. development of Contrave after
the FDA said a large study on heart risks would be required before the drug
could be approved -- a move the company called “unprecedented.”
Orexigen and partner Takeda Pharmaceutical Co. of Osaka, Japan, has been
vying with Mountain View, California-based Vivus Inc. (VVUS) and Arena
Pharmaceuticals Inc. (ARNA) of San Diego to introduce the first new obesity
medicine in the U.S. in more than a decade.
Shares Rise
Orexigen gained 63 percent to $2.40 at 4:33 p.m. New York time in extended
trading after the company’s shares were unchanged at $1.47 at the close of
Nasdaq Stock Market composite trading. Arena rose as much as 17 percent to $
1.69 and Vivus increased 5.5 percent to $9.10 in extended trading.
Orexigen’s shares had declined 75 percent in the past 12 months.
Last week, the FDA agreed to reconsider Vivus’s drug, Qnexa, for the
treatment of obese men and women who don’t have the potential for having
children. Under the agreement, Vivus will resubmit Qnexa by the end of next
month, with the FDA scheduling an advisory panel in the first quarter of
next year. A final decision on whether the drug is approved would come in
the second quarter of 2012, Vivus said.
Arena’s medicine, lorcaserin, was rejected by the FDA last October. The
agency requested more data after a rat study showed a possible link to brain
tumors. The company and its development partner Tokyo-based Eisai Co. said
in August that a study showed concentrations of their weight-loss pill were
lower in human brains than in rat models.
Seeking Partner
Contrave’s study won’t have the same patient restrictions as Vivus’s
Qnexa, Narachi said. The company, which had $70 million in cash at the end
of the last quarter, will look for a partner to help shoulder the cost of
the new trial, in exchange for commercial rights outside of North America.
Previous studies showed that two Contrave tablets taken two times a day
helped twice as many patients in studies lose at least 5 percent of their
weight compared with a placebo after 56 weeks, meeting one of two FDA
guidelines for approval of diet pills. The product is a combination of two
marketed drugs that target different parts of the brain influencing appetite
and cravings.
Contrave increases blood pressure, a risk seen with Abbott Laboratories pill
Meridia. The agency pulled Meridia from the market last year after it was
tied to heart attacks and strokes in a study.
While the FDA is planning to ask an advisory committee to review the general
requirements for heart safety and diet bills, any recommendations won’t
affect the agency’s agreement with Orexigen on Contrave, the company said
in its statement.
To contact the reporter on this story: Ryan Flinn in San Francisco at rflinn
@bloomberg.net
To contact the editor responsible for this story: Reg Gale at rgale5@
bloomberg.net |
|
